Victory Capital Management Inc. Has $20.17 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Victory Capital Management Inc. grew its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 19.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 629,387 shares of the company’s stock after buying an additional 103,404 shares during the quarter. Victory Capital Management Inc.’s holdings in SpringWorks Therapeutics were worth $20,166,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in SWTX. First Horizon Advisors Inc. grew its stake in SpringWorks Therapeutics by 47.9% during the second quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after buying an additional 383 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in SpringWorks Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after buying an additional 474 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in SpringWorks Therapeutics during the second quarter worth about $123,000. Quarry LP grew its stake in SpringWorks Therapeutics by 56.3% during the second quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $188,000 after buying an additional 1,800 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in SpringWorks Therapeutics during the third quarter worth about $209,000.

SpringWorks Therapeutics Stock Performance

SWTX opened at $34.56 on Tuesday. The firm’s fifty day moving average is $32.61 and its two-hundred day moving average is $36.94. The firm has a market cap of $2.57 billion, a PE ratio of -8.91 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a twelve month low of $20.19 and a twelve month high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.03. The company had revenue of $49.10 million for the quarter, compared to analyst estimates of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The business’s revenue for the quarter was up 4810.0% compared to the same quarter last year. During the same period last year, the business posted ($1.27) earnings per share. Equities analysts forecast that SpringWorks Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SWTX has been the topic of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a research note on Monday. HC Wainwright decreased their price target on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. increased their price target on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $68.17.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.